Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma
Translational Gastroenterology and Hepatology · 2026-07 · 11 · 77-77
DOI: 10.21037/tgh-2026-0046 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Gastroenterology and Hepatology, 2026-07. Verfasst von Arunkumar Krishnan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Supportive Oncology, Atrium Health Levine Cancer, Charlotte, NC, USA.
ORCID-Profile: Arunkumar Krishnan
Zitieren
APA
Krishnan, A., & Mukherjee, D. (2026). Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma. Translational Gastroenterology and Hepatology, 11, 77-77. https://doi.org/10.21037/tgh-2026-0046
Vancouver
Krishnan A, Mukherjee D. Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma. Translational Gastroenterology and Hepatology. 2026;11:77-77. doi:10.21037/tgh-2026-0046
BibTeX
@article{Krishnan2026,
author = {Krishnan, Arunkumar and Mukherjee, Diptasree},
title = {Adjuvant multimodality immunotherapy in resected high-risk pancreatic ductal adenocarcinoma},
journal = {Translational Gastroenterology and Hepatology},
year = {2026},
volume = {11},
pages = {77--77},
doi = {10.21037/tgh-2026-0046}
}
EUVIMED